Royal Bank of Canada Raises Stock Position in Heartflow, Inc. $HTFL

Royal Bank of Canada lifted its holdings in shares of Heartflow, Inc. (NASDAQ:HTFL) by 24.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 137,421 shares of the company’s stock after acquiring an additional 26,912 shares during the quarter. Royal Bank of Canada owned about 0.16% of Heartflow worth $3,343,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Rock Springs Capital Management LP raised its position in Heartflow by 106.2% in the first quarter. Rock Springs Capital Management LP now owns 572,500 shares of the company’s stock valued at $13,929,000 after purchasing an additional 294,800 shares during the period. Quantinno Capital Management LP purchased a new stake in shares of Heartflow in the first quarter worth about $1,734,000. Lazard Asset Management LLC purchased a new stake in shares of Heartflow in the first quarter worth about $928,000. Entropy Technologies LP acquired a new stake in shares of Heartflow in the first quarter valued at about $338,000. Finally, Sei Investments Co. lifted its position in Heartflow by 342.5% during the 1st quarter. Sei Investments Co. now owns 67,048 shares of the company’s stock worth $1,631,000 after acquiring an additional 51,895 shares in the last quarter.

Heartflow Stock Up 35.7%

HTFL stock opened at $42.08 on Friday. The stock’s 50 day moving average is $29.08 and its two-hundred day moving average is $27.80. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $43.00. The company has a market capitalization of $3.63 billion and a PE ratio of -22.99.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.50%. The business’s revenue was up 47.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Heartflow, Inc. will post -0.82 EPS for the current year.

Key Stories Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
• Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
• Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
• Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
• Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares

Insider Buying and Selling at Heartflow

In other Heartflow news, insider Campbell Rogers sold 9,219 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the completion of the transaction, the insider directly owned 78,731 shares of the company’s stock, valued at $2,231,236.54. This trade represents a 10.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 38,900 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the completion of the sale, the chief executive officer owned 457,935 shares in the company, valued at approximately $16,027,725. This trade represents a 7.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 115,805 shares of company stock valued at $3,530,609. 7.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HTFL. Benchmark reaffirmed a “buy” rating on shares of Heartflow in a research report on Friday. Weiss Ratings upgraded shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. William Blair started coverage on shares of Heartflow in a report on Monday, May 4th. They set an “outperform” rating for the company. Robert W. Baird set a $45.00 price target on shares of Heartflow in a research note on Friday. Finally, Morgan Stanley boosted their price objective on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.43.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.